Merck Mercuriadis, founder of the influential catalog investment group Hipgnosis, is preparing to launch a re-vamped version ...

I've written this kind of article before, addressing whether it's smart to buy into the dividend-paying stocks in the S&P 500 ...

Explore the Hipgnosis founder's new venture, focused on music management and co-ownership for artists and managers.

Merck Mercuriadis, the architect behind Hipgnosis’s transformation of music rights into a mainstream asset class, is making a ...

From health to hair care, the experts broke down exactly how artificial intelligence is shaping Black futures and why we can’t afford to sit this one out.

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

Sean “Diddy” Combs would have a hard time launching a comeback despite his acquittal on the most severe charges because of ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

US pharmaceutical companies will be forced to answer questions this week from lawmakers, who have been grilling them on their ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

A startling new vision of vaccination in America is becoming clearer — one likely to involve fresh scrutiny of established science and practices, and limits on vaccines that have been studied for ...